Kalaris Therapeutics (KLRS)

The company’s lead program is TH103, a clinical-stage anti-vascular endothelial growth factor drug candidate. VEGF is a key signaling protein involved in the formation and permeability of blood vessels, and anti-VEGF therapy is an established treatment approach in major retinal conditions such as wet age-related macular degeneration, diabetic macular edema, and other neovascular eye diseases. TH103 is engineered as a fully humanized recombinant fusion protein that acts as a decoy receptor, binding VEGF before it can activate pathways that contribute to disease progression.

Kalaris designed TH103 to leverage properties associated with the body’s native VEGF receptor 1, which has high affinity for VEGF. The company’s goal is to develop a therapy that may offer more durable or enhanced VEGF inhibition compared with existing options, although its clinical profile must be established through trials and regulatory review. As a development-stage company, Kalaris depends on clinical execution, data quality, regulatory progress, and access to capital. Its opportunity lies in a large ophthalmology market where physicians continue to seek treatments that preserve vision while reducing injection frequency and treatment burden.